Ranbaxy Officially Becomes A Daiichi Subsidiary As Management Turns To Business Synergies
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Daiichi Sankyo has acquired 52.5 percent of Ranbaxy's equity share capital for $736 million. Ranbaxy announced that the committee of the board of directors of Ranbaxy approved Oct. 20 the allotment of equity shares and warrants on a preferential basis to Daiichi Sankyo. With this Ranbaxy has officially become a subsidiary of Daiichi Sankyo
You may also be interested in...
Top Japanese Pharmas Show Appetite For Emerging Market Expansion, Will Generics Follow?
TOKYO - Japanese pharma companies are trying to determine how to expand into new markets, ranging from the U.S. to China, and IMS Health data show a slow move away from dependence on the domestic market for Japan's leading companies
Top Japanese Pharmas Show Appetite For Emerging Market Expansion, Will Generics Follow?
TOKYO - Japanese pharma companies are trying to determine how to expand into new markets, ranging from the U.S. to China, and IMS Health data show a slow move away from dependence on the domestic market for Japan's leading companies
Daiichi Sankyo Seeking Small Biotech Acquisitions In Europe
Daiichi Sankyo is scanning Europe for potential acquisitions that would help the Japanese company expand its market reach and enhance its product pipeline. Daiichi will focus on smaller biotechnology companies that have a strong oncology focus and a promising pipeline